Dr. Aletaha has received consulting or speaker's honoraria (less than $10,000 each) from Abbott, Sanofi-Aventis, Schering-Plough, and Wyeth.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Rheumatoid Arthritis
You have full text access to this OnlineOpen article
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
Article first published online: 28 SEP 2007
DOI: 10.1002/art.22943
Copyright © 2007 by the American College of Rheumatology
Additional Information
How to Cite
Aletaha, D., Funovits, J., Keystone, E. C. and Smolen, J. S. (2007), Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis & Rheumatism, 56: 3226–3235. doi: 10.1002/art.22943
Publication History
- Issue published online: 28 SEP 2007
- Article first published online: 28 SEP 2007
- Manuscript Accepted: 29 JUN 2007
- Manuscript Received: 13 FEB 2007
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , Disease Activity Assessment and Patient-Reported Outcomes in Patients with Early Rheumatoid Arthritis, Rheumatic Disease Clinics of North America, 2012,
- 2, , , Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year, Arthritis Care & Research, 2012, 64, 5Direct Link:
- 3, , , , , , , , , Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs, Arthritis Research & Therapy, 2012, 14, 1, R34
- 4
- 5, , , 28-joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project, Rheumatology, 2011, 50, 7, 1259
- 6, , , , , , Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial, Scandinavian Journal of Rheumatology, 2011, 40, 3, 232
- 7, , Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: Practical applications for rheumatology healthcare providers, Journal of the American Academy of Nurse Practitioners, 2011, 23, 9Direct Link:
- 8, , Optimal care for early RA patients: the challenge of translating scientific data into clinical practice, Rheumatology, 2011, 50, 7, 1194
- 9
- 10, , , , , , , , , , , , , , , , , , , , , , , Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA, Current Medical Research and Opinion, 2011, 27, 2, 315
- 11, , , , , , Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis, BMC Musculoskeletal Disorders, 2011, 12, 1, 120
- 12, , , , , , Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis, Clinical Rheumatology, 2011, 31, 4, 613
- 13, , , , , , , , Review of treatment response in rheumatoid arthritis: assessment of heterogeneity, Current Medical Research and Opinion, 2011, 27, 4, 697
- 14, , Treatment of Early Rheumatoid Arthritis: Concepts in Management, Seminars in Arthritis and Rheumatism, 2011, 40, 5, 371
- 15
- 16
- 17, , ¿El control precoz de la artritis reumatoide augura un mejor pronóstico a largo plazo?, ReumatologÃa ClÃnica, 2010, 6, 2, 106
- 18, , , , Antibodies against cyclic citrullinated peptide don’t decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis, Rheumatology International, 2010, 31, 11, 1439
- 19, , Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study, Modern Rheumatology, 2010, 20, 6, 539
- 20, , , , , , , , , , , , , , , BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology, 2010,
- 21, , , , C-reactive protein in gingival crevicular fluid may be indicative of systemic inflammation, Journal of Clinical Periodontology, 2010, 37, 9Direct Link:
- 22, , Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?, ReumatologÃa ClÃnica (English Edition), 2010, 6, 2, 106
- 23, , , , , , Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis, Annals of the New York Academy of Sciences, 2010, 1193, 1Direct Link:
- 24, , , , Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?, Rheumatology, 2010, 49, 6, 1201
- 25, , , , , , , Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis, Joint Bone Spine, 2009, 76, 4, 350
- 26, , , , , , Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis, Rheumatology, 2009, 48, 6, 686
- 27, , , , Incidence and nature of infectious disease in patients treated with anti-TNF agents, Autoimmunity Reviews, 2009, 9, 2, 67
- 28, , , , , Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline, Arthritis Care & Research, 2009, 61, 3Direct Link:
- 29, , , , , , , Polyarthrite rhumatoïde (PR) en rémission sous anti-TNF alpha. Évolution après interruption du traitement anti-TNF, Revue du Rhumatisme, 2009, 76, 7, 634
- 30, , , , , , , , , , , , , , , , , Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms, Rheumatology, 2009, 49, 3, 458
- 31, , , Prognostic factors in rheumatoid arthritis in the era of biologic agents, Nature Reviews Rheumatology, 2009, 5, 9, 491
- 32, Progression in early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 2009, 23, 1, 59
- 33, , , , , , Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients, Rheumatology, 2009, 48, 12, 1575
- 34, , , , , , Traitement actuel de la polyarthrite rhumatoïde, La Revue de Médecine Interne, 2009, 30, 12, 1067
- 35
- 36
- 37, , Activity assessments in rheumatoid arthritis, Current Opinion in Rheumatology, 2008, 20, 3, 306
- 38, , Biologic therapy for early rheumatoid arthritis: the latest evidence, Current Opinion in Rheumatology, 2008, 20, 3, 314
- 39, , Biologic therapy for early rheumatoid arthritis: the latest evidence, Current Opinion in Internal Medicine, 2008, 7, 4, 415
- 40, , , , Innovative treatment strategies for patients with rheumatoid arthritis, Current Opinion in Rheumatology, 2008, 20, 3, 287
- 41, , Monitoring disease activity in rheumatoid arthritis: an imperative, Future Rheumatology, 2008, 3, 2, 99
- 42, , , Stratégies thérapeutiques actuelles dans les principaux rhumatismes inflammatoires chroniques, Actualités Pharmaceutiques Hospitalières, 2008, 4, 14, 26
- 43, , Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement, Rheumatology, 2008, 47, 11, 1600
- 44, , The burden of rheumatoid arthritis and access to treatment: a medical overview, The European Journal of Health Economics, 2007, 8, S2, 39